Get the Stockscreener App
0.75
7.16%
0.0501
Co Diagnostics Inc stock is traded at $0.75, with a volume of 640.90K.
It is up +7.16% in the last 24 hours and down -15.81% over the past month.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
See More
Previous Close:
$0.6999
Open:
$0.688
24h Volume:
640.90K
Relative Volume:
5.01
Market Cap:
$23.95M
Revenue:
$7.11M
Net Income/Loss:
$-41.28M
P/E Ratio:
-0.6048
EPS:
-1.24
Net Cash Flow:
$-26.84M
1W Performance:
-2.34%
1M Performance:
-15.81%
6M Performance:
-40.00%
1Y Performance:
-43.61%
1-Day Range:
$0.688
$0.79
1-Week Range:
$0.67
$0.79
52-Week Range:
$0.67
$2.2299
Co Diagnostics Inc Stock (CODX) Company Profile
Name
Co Diagnostics Inc
Sector
Industry
Phone
(801) 278-9769
Address
4049 SOUTH HIGHLAND DRIVE, SALT LAKE CITY
Compare CODX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CODX
Co Diagnostics Inc
|
0.75 | 23.95M | 7.11M | -41.28M | -26.84M | -1.38 |
|
ABT
Abbott Laboratories
|
113.11 | 196.18B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
360.05 | 137.26B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
89.32 | 131.64B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
79.88 | 102.43B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.03 | 43.66B | 6.60B | 4.16B | 490.10M | 6.93 |
Co Diagnostics Inc Stock (CODX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-22 | Downgrade | Sidoti | Buy → Neutral |
| Dec-29-21 | Initiated | Sidoti | Buy |
| Mar-29-21 | Downgrade | Maxim Group | Buy → Hold |
| May-20-20 | Upgrade | Maxim Group | Hold → Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Downgrade | Maxim Group | Buy → Hold |
View All
Co Diagnostics Inc Stock (CODX) Latest News
Co-Diagnostics stock plunges to 52-week low at $0.69 By Investing.com - Investing.com Canada
Co-Diagnostics (NASDAQ:CODX) and Aethlon Medical (NASDAQ:AEMD) Critical Review - Defense World
Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Rele - GuruFocus.com
Financial Review: Co-Diagnostics (NASDAQ:CODX) & Endologix (OTCMKTS:ELGXQ) - Defense World
Co-Diagnostics stock hits 52-week low at $0.79 amid market challenges - Investing.com
CoSara Diagnostics inaugurates new oligo facility in Ranoli, Gujarat - BSI bureau
Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility - Marketscreener.com
Co-Diagnostics, Inc. Announces Third Quarter 2024 Earnings Release Date and Webcast - The Eastern Progress Online
Co-Diagnostics, Inc. to Accompany Utah Governor and WTC Utah on Trade Mission to South Korea and Japan - The Eastern Progress Online
Telugu News, Tollywood News, Andhra, Telangana, Southఇండియా హెరాల్డ్ గ్రూప్ అఫ్ పబ్లిషర్స్ ప్రై లిమిటెడ్ - ఇండియా హెరాల్డ్ గ్రూప్ అఫ్ పబ్లిషర్స్ ప్రై లిమిటెడ్ - India Herald Group of Publishers P LIMITED
Co-Diagnostics stock hits 52-week low at $0.85 amid market challenges - Investing.com Canada
Co-Diagnostics (FRA:C97) Earnings Yield % : N/A% (As of Dec. 05, 2024) - GuruFocus.com
Co-Diagnostics (FRA:C97) Enterprise Value : €-6.97 Mil (As of Dec. 05, 2024) - GuruFocus.com
Co-Diagnostics (STU:C97) Momentum Rank : 7 (As of Dec. 05, 2024) - GuruFocus.com
Co-Diagnostics (FRA:C97) EBITDA per Share : €-1.18 (TTM As of Sep. 2024) - GuruFocus.com
Co-Diagnostics (FRA:C97) 3-Year FCF Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Co-Diagnostics (HAM:C97) Price-to-Operating-Cash-Flow : (As of Dec. 01, 2024) - GuruFocus.com
Co-Diagnostics (HAM:C97) 50-Day SMA : €1.07 (As of Nov. 30, 2024) - GuruFocus.com
Rabies Diagnostics Market Report Details Trends and Growth Analysis Report 2024 - WhaTech
Co-Diagnostics (HAM:C97) Cash Flow from Operations : €-23.54 Mil (TTM As of Sep. 2024) - GuruFocus.com
Co-Diagnostics (HAM:C97) Forward Rate of Return (Yacktman) % : 0.00% (As of Sep. 2024) - GuruFocus.com
Co-Diagnostics (HAM:C97) Change In Inventory : €0.32 Mil (TTM As of Sep. 2024) - GuruFocus.com
Co-Diagnostics (HAM:C97) Forward Dividend Yield % : 0.00% (As of Nov. 26, 2024) - GuruFocus.com
CODX (Co-Diagnostics) 3-Year Book Growth Rate : 5.60% (As of Sep. 2024) - GuruFocus.com
Co-Diagnostics stock hits 52-week low at $1 amid market challenges - Investing.com Australia
CODX (Co-Diagnostics) Momentum Rank : 8 (As of Nov. 26, 2024) - GuruFocus.com
Co-Diagnostics, Inc. to Host Booth at the 2024 UHCA/UCAL Fall Convention & Expo on Oct 2-3 - GuruFocus.com
Co-Diagnostics stock hits 52-week low at $1 amid market challenges By Investing.com - Investing.com South Africa
CODX (Co-Diagnostics) 3-Year EPS without NRI Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Co-Diagnostics (HAM:C97) Cash Flow from Discontinued Operat - GuruFocus.com
Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results - GuruFocus.com
Co-Diagnostics (LTS:0A50) Total Liabilities : $8.60 Mil (As of Sep. 2024) - GuruFocus.com
Daxor (NASDAQ:DXR) & Co-Diagnostics (NASDAQ:CODX) Critical Survey - Defense World
Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Leading Molecular Diagnostics Company BillionToOne Announces Three Executive Appointments Amid Rapid Growth - PR Newswire
Co-Diagnostics Q3 2024 Earnings Preview - MSN
Co-Diagnostics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Co-Diagnostics, Inc. (NASDAQ:CODX) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Co-Diagnostics reports decreased Q3 revenue, eyes growth By Investing.com - Investing.com Australia
Co-Diagnostics Inc (CODX) Q3 2024 Earnings Call Highlights: Navi - GuruFocus.com
Co-Diagnostics Inc (CODX) Q3 2024 Earnings Call Highlights: Navigating Revenue Decline and ... - Yahoo Finance
Co-Diagnostics Reports Q3 2024 Financial Results - TipRanks
Co-Diagnostics earnings beat by $0.01, revenue topped estimates - Investing.com UK
CODX (Co-Diagnostics) GF Value Rank : 0 (As of Nov. 05, 2024) - GuruFocus.com
Co-Diagnostics, Inc. to Host Booth at MEDICA Trade Fair in Düsseldorf, Germany on Nov 11-14, 2024 - PR Newswire
Analyzing Insulet (NASDAQ:PODD) and Co-Diagnostics (NASDAQ:CODX) - Defense World
Co-Diagnostics, Inc. Announces Third Quarter 2024 Earnings Relea - GuruFocus.com
Is Co-Diagnostics (NASDAQ:CODX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Co Diagnostics Inc Stock (CODX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):